Swiss Cardio Technologies acquired by Abacus Medicine Group

Swiss Cardio Technologies was founded in 2008 by a group of cardiovascular surgery specialists from the University of Berne including Thierry Carrel, focusing on the development of cardiovascular medical products. Their flagship product, Cardioplexol is a novel, ultra-low volume cardioplegic solution designed for use during cardiac surgery to achieve rapid and safe cardiac arrest, primarily benefiting procedures such as coronary artery bypass grafting (CABG) and aortic repairs.

Following more than a decade of development, clinical trials, and regulatory approval, the company began commercial activities in Switzerland in 2023 with ambitions to expand further into Europe and globally. Today, the solution holds marketing approvals in 10 European Union countries and Switzerland.

Swiss Cardio Technologies, which has extensive, long-term relationships with global opinion leaders in cardiothoracic surgery, has been acquired by Abacus Medicine Group, a pharmaceutical company based in Denmark. The Group has more than 1,500 employees and achieved revenue of EUR 1,487 million from sales in 35 countries globally in 2024. By joining forces, the two companies will considerably accelerate the ongoing commercialization and international expansion of the current business.

The acquisition includes the global rights for Swiss Cardio Technology’s cardioplegia business. Cardioplegia is a technique used to intentionally and temporarily interrupt cardiac activity to facilitate bypass surgery or other cardiac and aortic repairs that require an immobile heart.

Flemming Wagner, CEO and founder of the Abacus Medicine Group, says: “Swiss Cardio Technologies exemplifies excellence in healthcare innovation. The opportunities for our two organizations are significant, and I look forward to exploring them together. This acquisition of our first pharmaceutical asset is a strategic addition to the Group’s business model and our plans for continued profitable growth. It marks the beginning of a new chapter.”

Professor Thierry Carrel from Swiss Cardio Technologies says: “We are deeply rooted in cardiovascular surgery and research, and our aim has always been to connect academia and industry. Today, we have accomplished exactly that. In Abacus Medicine Group, we have found the right, dedicated partner to drive the growth of the business.”

(Press release/RAN)